SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

* Histologically confirmed advanced malignancy defined as any of the following tumors for which no further standard or curative therapy exists or is considered appropriate by the Investigator: * Epithelial ovarian cancer, including fallopian tube cancer or primary peritoneal cancer, of high-grade serous histology, with platinum refractory or resistant disease after prior treatment with at least one platinum-based chemotherapeutic regimen. In Part B (dose expansion), subjects may have received no more than 3 lines of systemic cytotoxic chemotherapy. * Note, the line of therapy limit does not apply to the biopsy substudy cohorts. * Metastatic or advanced endometrial carcinoma previously treated with at least 1 platinum-based chemotherapeutic regimen. * Eastern Cooperative Oncology Group (ECOG) 0-1. * Adequate hematologic, hepatic, and renal function.

* Participants with prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine based drug.